Shattuck Labs
About
Overview
Our Origins
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
SEC Filings
Quarterly Results
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
IR Resources
FAQS
Email Alerts
IR & Media Contact
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
Current Openings
Contact
Locations
Contact Us
Our Science
Our Science
About
Overview
Our Origins
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
SEC Filings
Quarterly Results
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
IR Resources
FAQS
Email Alerts
IR & Media Contact
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
Current Openings
Contact
Locations
Contact Us
Publications
Year
All
2022
2019
The Journal of Immunology
September 22, 2022
Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2+ T Cells in the Presence of Costimulation by CD28 or NKG2D
The Journal of Immunology
July 11, 2022
LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade
Cancer Immunology Research
December 20, 2019
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
Journal for ImmunoTherapy of Cancer
January 25, 2019
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
The Journal of Immunology
September 22, 2022
Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2+ T Cells in the Presence of Costimulation by CD28 or NKG2D
The Journal of Immunology
July 11, 2022
LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade
Cancer Immunology Research
December 20, 2019
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
Journal for ImmunoTherapy of Cancer
January 25, 2019
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
About
Overview
Our Origins
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
SEC Filings
Quarterly Results
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
IR Resources
FAQS
Email Alerts
IR & Media Contact
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
Current Openings
Contact
Locations
Contact Us
Follow Us
